dc.creator | Magouliotis D.E., Christodoulidis G., Zacharoulis D. | en |
dc.date.accessioned | 2023-01-31T08:55:42Z | |
dc.date.available | 2023-01-31T08:55:42Z | |
dc.date.issued | 2020 | |
dc.identifier | 10.1007/s11695-020-04535-y | |
dc.identifier.issn | 09608923 | |
dc.identifier.uri | http://hdl.handle.net/11615/76077 | |
dc.description.abstract | [No abstract available] | en |
dc.language.iso | en | en |
dc.source | Obesity Surgery | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85081720086&doi=10.1007%2fs11695-020-04535-y&partnerID=40&md5=714ae26f1d6fc501702ed74b97d945e4 | |
dc.subject | cholesterol | en |
dc.subject | glycoprotein | en |
dc.subject | ursodeoxycholic acid | en |
dc.subject | ursodeoxycholic acid | en |
dc.subject | bariatric surgery | en |
dc.subject | body weight loss | en |
dc.subject | cholecystectomy | en |
dc.subject | cholelithiasis | en |
dc.subject | drug efficacy | en |
dc.subject | drug safety | en |
dc.subject | drug tolerability | en |
dc.subject | human | en |
dc.subject | incidence | en |
dc.subject | Letter | en |
dc.subject | morbidity | en |
dc.subject | mortality risk | en |
dc.subject | operation duration | en |
dc.subject | postoperative complication | en |
dc.subject | priority journal | en |
dc.subject | Roux-en-Y gastric bypass | en |
dc.subject | surgical mortality | en |
dc.subject | surgical risk | en |
dc.subject | bariatrics | en |
dc.subject | cholelithiasis | en |
dc.subject | gastric bypass surgery | en |
dc.subject | morbid obesity | en |
dc.subject | Bariatric Surgery | en |
dc.subject | Bariatrics | en |
dc.subject | Cholelithiasis | en |
dc.subject | Gastric Bypass | en |
dc.subject | Humans | en |
dc.subject | Incidence | en |
dc.subject | Obesity, Morbid | en |
dc.subject | Ursodeoxycholic Acid | en |
dc.subject | Springer | en |
dc.title | The Necessity for Routine Administration of Ursodeoxycholic Acid After Bariatric Surgery | en |
dc.type | other | en |